AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, ABVI characterizes an investment’s success by its potential to significantly increase AbbVie’s strategic growth, and not solely by its financial return.
AbbVie is a stockholder of Kala and has the right to appoint one director to the nine member Kala Board. AbbVie is not otherwise affiliated with Kala and AbbVie does not control, is not controlled by and is not under common control with Kala and is not an affiliate as defined under any applicable statute, rule, regulation or law.
Lux Capital Management is a New York-based venture capital firm focused on early stage investments in the physical and life sciences. Collectively, the investment team at Lux has started more than 20 companies including Nanosys, Vertex [VRTX], Illumina [ILMN], Caliper Technologies [CALP], Neurocrine Biosciences [NBIX], Lux Research, and Idun (acquired by Pfizer [PFE]).
Polaris invests in seed, early stage and middle market companies in high growth industries. As the lead or co-lead investor, Polaris takes an active and long-term role in helping management teams build highly successful businesses. Polaris has over $3 billion under management and current investments in more than 90 companies.
Third Rock Ventures is a premier venture firm focused on life sciences, investing and launching companies that make a difference in people's lives. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for a rapidly growing and highly successful life sciences company. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance.
Ysios Capital is an independent venture capital firm providing private equity financing to early through late-stage human healthcare and biotechnology companies with special focus on pharmaceuticals, diagnostics and medical devices. Ysios launched its first 69 million Euro fund Ysios BioFund I in 2008. Ysios has invested in 11 companies, and has successfully exited from BioVex (sold to Amgen for up to 1 billion USD) and from Endosense (sold to St. Jude Medical for up to 325 million CHF), and floated adult stem cell therapy company Cellerix on the NYSE Euronext Brussels through a reverse merger with Tigenix. The current active portfolio of Ysios BioFund I includes AM-Pharma (The Netherlands), Cardoz (Sweden), CVRx (United States), Inbiomotion (Spain), Medlumics (Spain), STAT-Diagnostica (Spain), TIG:BB Tigenix (Belgium) and Kala (United States).